4jn2
From Proteopedia
(Difference between revisions)
| (5 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_4jn2| PDB=4jn2 | SCENE= }} | ||
| - | ===An Antidote for Dabigatran=== | ||
| - | {{ABSTRACT_PUBMED_23476049}} | ||
| - | == | + | ==An Antidote for Dabigatran== |
| - | [[4jn2]] is a 4 chain structure with sequence from [ | + | <StructureSection load='4jn2' size='340' side='right'caption='[[4jn2]], [[Resolution|resolution]] 1.71Å' scene=''> |
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4jn2]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JN2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4JN2 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.71Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4CC:N-[(2-{[(4-CARBAMIMIDOYLPHENYL)AMINO]METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL]-N-PYRIDIN-2-YL-BETA-ALANINE'>4CC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4jn2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jn2 OCA], [https://pdbe.org/4jn2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4jn2 RCSB], [https://www.ebi.ac.uk/pdbsum/4jn2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4jn2 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Key points We present an antidote for dabigatran that effectively reverses its anticoagulative effect in human plasma in vitro and in rats in vivo.The antidote shares structural features with thrombin in the mode of binding, but has no activity in coagulation tests. | ||
| - | + | A specific antidote for dabigatran: functional and structural characterization.,Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T Blood. 2013 Mar 8. PMID:23476049<ref>PMID:23476049</ref> | |
| - | <ref | + | |
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 4jn2" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Mus musculus]] | [[Category: Mus musculus]] | ||
| - | [[Category: Nar | + | [[Category: Nar H]] |
| - | [[Category: Schiele | + | [[Category: Schiele F]] |
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
An Antidote for Dabigatran
| |||||||||||
